Study identifier:NXL104/2001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective, multicenter, investigator-blinded, randomized, comparative study estimate safety, tolerability, efficacy of NXL104/ceftazidime vs. comparator followed appropriate oral therapy treatment complicated UTI hosp adults
Complicated urinary tract infection
Phase 2
No
NXL104/ceftazidime, Imipenem/Cilastatin
All
137
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Verified 01 Dec 2011 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 NXL/104 ceftazidime | Drug: NXL104/ceftazidime 125mg/500mg TID Drug: NXL104/ceftazidime 125mg/500mg TID |
Active Comparator: 2 comparator 4 x daily | Drug: Imipenem/Cilastatin 4 x daily |